Active	Status	Sponsor type	Region	Phase	Filter
13 Active 5 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grupp, Stephan A
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study	Recruiting	3	1400	Europe, Canada, Japan, US, RoW	Previously treated CAR-T patients	Novartis Pharmaceuticals, University of Pennsylvania	Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program	02/36	02/36
NCT03601442: CTL019 Out of Specification MAP for ALL or DLBCL Patients	Available	N/A		Canada, US, RoW	CTL019, tisagenlecleucel, Kymriah	Novartis Pharmaceuticals	Acute Lymphoblastic Leukemia (ALL), Diffuse Large B-cell Lymphoma (DLBCL)
Varghese, Melissa
22CT012, NCT05650749: GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma	Recruiting	1	30	US	GPC2 CAR T cells	Stephan Grupp MD PhD, Children's Hospital of Philadelphia, Tmunity Therapeutics, University of Pennsylvania	Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma	01/25	01/26